Product nameAnti-CD44v6 antibody [VFF-18]
See all CD44v6 primary antibodies
DescriptionMouse monoclonal [VFF-18] to CD44v6
SpecificitySpecific for an epitope encoded by exon v6 on the variant portion of human CD44.
Tested applicationsSuitable for: WB, IHC-P, ICC, Flow Cyt, IHC-Frmore details
Species reactivityReacts with: Human
Fusion protein corresponding to Human CD44v6. Glutathione S Transferase (GST) fusion protein corresponding to the variable domain v6 of human CD44.
Database link: P16070
EpitopeSpecific for an epitope encoded by exon v6 on the variant portion of human CD44.
This product was changed from ascites to tissue culture supernatant on 15th August 2017. The highest lot of ascites still in stock on 15th August 2017 is GR295277-3 . Lot numbers higher than GR295277-3 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferConstituent: PBS
Concentration information loading...
Purification notesPurity: >95%.
Our Abpromise guarantee covers the use of ab78960 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Detects a band of approximately 91 kDa (predicted molecular weight: 82 kDa).|
|IHC-P||Use at an assay dependent concentration.|
|Flow Cyt||Use 1µg for 106 cells.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionReceptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Adhesion with HA plays an important role in cell migration, tumor growth and progression. In cancer cells, may play an important role in invadopodia formation. Also involved in lymphocyte activation, recirculation and homing, and in hematopoiesis. Altered expression or dysfunction causes numerous pathogenic phenotypes. Great protein heterogeneity due to numerous alternative splicing and post-translational modification events.
Tissue specificityIsoform 10 (epithelial isoform) is expressed by cells of epithelium and highly expressed by carcinomas. Expression is repressed in neuroblastoma cells.
Sequence similaritiesContains 1 Link domain.
DomainThe lectin-like LINK domain is responsible for hyaluronan binding.
modificationsProteolytically cleaved in the extracellular matrix by specific proteinases (possibly MMPs) in several cell lines and tumors.
N- and O-glycosylated. O-glycosylation contains more-or-less-sulfated chondroitin sulfate glycans, whose number may affect the accessibility of specific proteinases to their cleavage site(s). It is uncertain if O-glycosylation occurs on Thr-637 or Thr-638.
Phosphorylated; activation of PKC results in the dephosphorylation of Ser-706 (constitutive phosphorylation site), and the phosphorylation of Ser-672.
Cellular localizationMembrane. Colocalizes with actin in membrane protrusions at wounding edges.
- Information by UniProt
- CD44 antibody
- CD44 antigen antibody
- CD44 isoform(s) antibody
All lanes : Anti-CD44v6 antibody [VFF-18] (ab78960) at 1 µg/ml ((Ascites))
Lane 1 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 2 : Caco 2 (Human colonic carcinoma cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 82 kDa
Observed band size: 91 kDa why is the actual band size different from the predicted?
Additional bands at: 36 kDa, 40 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 12 minutes
CD44v6 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
ab78960 (Ascites) staining CD44v6 in human breast cancer tissue by Immunohistochemistry (Frozen sections).Tissue was fixed in methanol and then blocked using 10% serum for 5 minutes at 25°C. Samples were then incubated with ab78960 at a 1/500 dilution for 1 hour at 25°C. The secondary used was an undiluted HRP conjugated goat polyclonal.
Overlay histogram showing THP1 cells stained with ab78960 (Ascites) (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab78960, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.
Immunocytochemical analysis of methanol fixed cultured human breast epithelial organoids labeling CD44v6 with ab78960 (Ascites) at 1/500 dilution. UltraVision ONE HRP Polymer was used as the secondary antibody. 10% serum was used as the blocking agent.
IHC image of ab78960 (Ascites) staining in human breast carcinoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab78960, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
This product has been referenced in:
- Toden S et al. Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight 4:N/A (2019). Read more (PubMed: 30895943) »
- Nagata H et al. LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer. Br J Cancer 120:996-1002 (2019). Read more (PubMed: 31000786) »